Skip to content

Rubidium-82 Position Emission Computed Tomography (PET) Versus Gated, Rest / Stress Technetium 99-m SPECT

A Prospective Comparison of Gated, Rest/Stress Rubidium-82 Position Emission Computed Tomography (PET) vs. Gated, Rest / Stress Technetium 99-m SPECT

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01179230
Acronym
PETvsSPECT
Enrollment
136
Registered
2010-08-11
Start date
2005-01-31
Completion date
2012-12-31
Last updated
2015-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Heart Disease, Myocardial Ischemia

Keywords

CAD, chest pain, acute coronary syndrome, Myocardial perfusion imaging

Brief summary

Many stress tests being done today have two parts, the stress test and the pictures of your heart. The investigators are comparing a newer technique to obtain the pictures (PET imaging) to the standard method (SPECT imaging). However, it is not known if the new test is better than the old test. It is important to have a standard to compare these tests to, and that is why people who will be getting a cardiac catheterization are being asked to participate. The information about your arteries from the cardiac catheterization will be used to judge which stress test is better. The investigators hypothesize that the newer method (PET imaging) will be more accurate than the old method (SPECT) in detecting heart disease.

Detailed description

A SPECT rest image will be obtained using a technetium based isotope. On a separate day, a Rubidium rest PET image will be obtained prior to a Dipyridamole stress test. Subjects will receive both Rubidium and technetium isotopes following the Dipyridamole stress, and will undergo first PET imaging and later SPECT imaging following the stress test. Patients will then go for cardiac catheterization as clinically ordered by their physician.

Interventions

Dipyridamole stress testing 0.57 mg/kg

OTHERPET imaging

Dipyridamole stress test 0.57 mg/kg with Rubidium PET images

Sponsors

Bracco Diagnostics, Inc
CollaboratorINDUSTRY
Hartford Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* referred for clinical cardiac catheterization

Exclusion criteria

* previous CABG * previous MI * Asthma or obstructive airway disease * Intolerance to Dipyridamole * Moderate to severe valvular disease * Cardiomyopathy - (ejection fraction less than 45%)

Design outcomes

Primary

MeasureTime frame
Coronary Artery Disease30 days

Secondary

MeasureTime frame
Myocardial Ischemia30 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026